Worldwide Appraisal and Update (2010) of Telavancin Activity Tested against a Collection of Gram-Positive Clinical Pathogens from Five Continents

A total of 15,480 Gram-positive pathogens were collected from 89 sites in the United States, Europe, the Asia-Pacific region, and Latin America in 2010. Telavancin was active against indicated Staphylococcus aureus (MIC50/90, 0.12/0.25 mu g/ml), vancomycin-susceptible Enterococcus faecalis (MIC50/90, 0.5/0.5 mu g/ml), and beta-hemolytic (MIC50/90, 0.06/0.12 mu g/ml) and viridans group streptococcus (MIC50/90, 0.03/0.06 mu g/ml) isolates. These MIC results showed potency for telavancin equal to or greater than that of comparators. These in vitro data confirm a continued potent activity of telavancin when tested against contemporary Gram-positive clinical isolates.